Even if your body releases a lot more of the 'muscle-building' hormones after a workout, it doesn’t mean you’ll grow more muscle than someone whose hormone levels stay low—studies show both groups end up with the same muscle size.

A double-blind, placebo-controlled RCT in healthy adult men and women where acute post-exercise hormone levels are artificially manipulated (e.g., via exogenous hormone infusion or suppression) to create 4–5 fold differences in testosterone, GH, and IGF-1, while controlling for training volume and nutrition. Muscle protein synthesis is measured via stable isotope tracer methods over 24–48h post-exercise, and long-term hypertrophy is tracked via DEXA or MRI over 8–12 weeks. Comparator groups: high-hormone vs. low-hormone conditions.

A prospective longitudinal cohort study tracking individuals undergoing identical resistance training programs, measuring endogenous post-exercise hormone spikes (testosterone, GH, IGF-1) via serial blood sampling after each session, and correlating these with muscle protein synthesis rates and hypertrophy over 12 weeks. Participants are stratified into high-responders (4–5x hormone spike) vs. low-responders based on natural variation.

A within-subject crossover design where each participant undergoes two 6-week training blocks: one with pharmacological suppression of post-exercise hormone rise (e.g., using GnRH antagonist or GH receptor blocker), and one with no suppression. Hormone levels and muscle outcomes are compared within individuals.

A systematic review and meta-analysis of all published RCTs comparing muscle hypertrophy outcomes in groups with documented 4–5 fold differences in post-exercise anabolic hormone levels, controlling for training variables.

An in vitro study exposing human myotubes to physiological vs. 4–5x supraphysiological concentrations of testosterone, GH, and IGF-1 to assess direct effects on protein synthesis pathways (e.g., mTOR activation, ribosomal biogenesis).